First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma
a study on Diffuse Large B-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma Mantle Cell Lymphoma Small Lymphocytic Lymphoma Leukemia
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at San Francisco, California and other locations
- Dates
- study startestimated completion
Description
Summary
The trial is a global, multi-center safety and efficacy trial of epcoritamab, an antibody also known as EPKINLY™ and GEN3013 (DuoBody®-CD3xCD20). The trial consists of 3 parts:
- a dose-escalation part (Phase 1, first-in-human (FIH))
- an expansion part (Phase 2a)
- a dose-optimization part (Phase 2a)
Official Title
A Phase 1/2, Open-label Safety Trial of GEN3013 in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma
Details
The purpose of the dose-escalation part of the trial is to determine the maximum tolerated dose (MTD) and the recommended Phase 2 dose (RP2D), as well as to establish the safety profile of epcoritamab in patients with relapsed, progressive or refractory B-cell lymphoma.
In the expansion part, additional patients will be treated with epcoritamab, at the RP2D and the purpose is to further explore and determine the safety and efficacy of epcoritamab.
The dose-optimization part will evaluate alternative priming and intermediate dose regimens of epcoritamab. All patients will receive epcoritamab at the RP2D.
Keywords
Diffuse Large B-cell Lymphoma (DLBCL), High-grade B-cell Lymphoma (HGBCL), Primary Mediastinal Large B-cell Lymphoma (PMBCL), Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), Small Lymphocytic Lymphoma (SLL), Marginal Zone Lymphoma (MZL), Lymphoma, B-Cell Lymphoma, Mantle-Cell Lymphoma, Lymphoma, Large B-Cell, Diffuse, Leukemia, Lymphocytic, Chronic, B-Cell, Epcoritamab
Eligibility
You can join if…
Open to people ages 18 years and up
Escalation Part (recruitment completed)
- Documented CD20+ mature B-cell neoplasm 1. DLBCL - de novo or transformed 2. HGBCL 3. PMBCL 4. FL 5. MCL 6. SLL 7. MZL (nodal, extranodal or mucosa associated) - Relapsed, progressive and/or refractory disease following treatment with an anti-CD20 monoclonal antibody (e.g. rituximab) potentially in combination with chemotherapy and/or relapsed after autologous stem cell rescue. - ECOG performance status 0,1 or 2 - Patients must have measurable disease by CT, MRI or PET-CT scan - Acceptable renal function - Acceptable liver function Main Inclusion Criteria - Expansion & Optimization Parts - Documented CD20 positive mature B cell neoplasm or CD20+ MCL - DLBCL, de novo or transformed (including double hit or triple hit) - PMBCL - FL grade 3B - Histologic confirmed FL - MZL - SLL - MCL (prior BTKi or intolerant to BTKi) - At least 2 therapies including an anti-CD20 monoclonal antibody containing chemotherapy combination regimen - Either failed prior autologous hematopoietic stem cell transplantation or ineligible for autologous stem cell transplantation due to age or comorbidities - At least 1 measurable site of disease based on CT, MRI or PET-CT scan with involvement of 2 or more clearly demarcated lesions and or nodes
You CAN'T join if...
All Parts
- Primary central nervous system (CNS) lymphoma or CNS involvement by lymphoma at screening - Known past or current malignancy other than inclusion diagnosis - AST, and/or ALT >3 × upper limit of normal - Total bilirubin >1.5 × upper limit of normal, unless bilirubin rise is due to Gilbert's syndrome or of non-hepatic origin - Estimated CrCl <45 mL/min - Known clinically significant cardiovascular disease - Ongoing active bacterial, viral, fungal, mycobacterial, parasitic, or other infection requiring systemic treatment (excluding prophylactic treatment). Past COVID-19 infection may be a risk factor - Confirmed history or current autoimmune disease or other diseases resulting in permanent immunosuppression or requiring permanent immunosuppressive therapy - Seizure disorder requiring therapy (such as steroids or anti-epileptics) - Any prior therapy with an investigational bispecific antibody targeting CD3 and CD20 - Prior treatment with chimeric antigen receptor T-cell (CAR-T) therapy within 30 days prior to first epcoritamab administration - Eligible for curative intensive salvage therapy followed by high dose chemotherapy with HSCT rescue - Autologous HSCT within 100 days prior to first epcoritamab administration, or any prior allogeneic HSCT or solid organ transplantation - Active hepatitis B (DNA PCR-positive) or hepatitis C (RNA PCR-positive infection). Subjects with evidence of prior HBV but who are PCR-negative are permitted in - Known human immunodeficiency virus (HIV) infection - Exposed to live or live attenuated vaccine within 4 weeks prior to signing ICF - Pregnancy or breast feeding - Patient is known or suspected of not being able to comply with the study protocol or has any condition for which, participation would not be in the best interest of the patient - Contraindication to all uric acid lowering agents NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Locations
- University of California at San Francisco
accepting new patients
San Francisco California 94117 United States - Arizona Mayo Clinic
accepting new patients
Phoenix Arizona 85054 United States
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Genmab
- ID
- NCT03625037
- Phase
- Phase 1/2 research study
- Study Type
- Interventional
- Participants
- Expecting 786 study participants
- Last Updated
Frequently Asked Questions
Please contact me about this study
We will not share your information with anyone other than the team in charge of this study. Submitting your contact information does not obligate you to participate in research.
Thank you!
The study team should get back to you in a few business days.
You will also receive an email with next steps. Check your junk/spam folder if needed.
If you do not hear from the study team, please call 888-689-8273 and tell them you’re interested in study number NCT03625037.